# Corsair Gaming, Inc.: financial statements, quarterly

CRSR · Nasdaq · CIK 1743759 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crsr.md) · [Financials](/companies/crsr/financials.md) · [Filings](/companies/crsr/filings.md) · [Insiders](/companies/crsr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crsr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [363](/filings/0000950170-24-122439.md) | [417 d](/filings/0001193125-26-067833.md) | [337](/filings/0000950170-25-064667.md) | [261](/filings/0000950170-25-105191.md) | [304](/filings/0001193125-25-264750.md) | [414 d](/filings/0001193125-26-067833.md) | [370](/filings/0001193125-26-211947.md) | [320](/filings/0001193125-26-337981.md) | [346](/filings/0001193125-25-264750.md) | [437 d](/filings/0001193125-26-067833.md) | [355](/filings/0001193125-26-211947.md) | [314](/filings/0001193125-26-337981.md) |
| Cost of revenue | $m | [274](/filings/0000950170-24-122439.md) | [315 d](/filings/0001193125-26-067833.md) | [251](/filings/0000950170-25-064667.md) | [198](/filings/0000950170-25-105191.md) | [235](/filings/0001193125-25-264750.md) | [305 d](/filings/0001193125-26-067833.md) | [267](/filings/0001193125-26-211947.md) | [234](/filings/0001193125-26-337981.md) | [253](/filings/0001193125-25-264750.md) | [292 d](/filings/0001193125-26-067833.md) | [238](/filings/0001193125-26-211947.md) | [210](/filings/0001193125-26-337981.md) |
| Gross profit | $m | [89.4](/filings/0000950170-24-122439.md) | [103 d](/filings/0001193125-26-067833.md) | [86.6](/filings/0000950170-25-064667.md) | [63.1](/filings/0000950170-25-105191.md) | [69.7](/filings/0001193125-25-264750.md) | [108 d](/filings/0001193125-26-067833.md) | [102](/filings/0001193125-26-211947.md) | [85.9](/filings/0001193125-26-337981.md) | [93.1](/filings/0001193125-25-264750.md) | [145 d](/filings/0001193125-26-067833.md) | [116](/filings/0001193125-26-211947.md) | [104](/filings/0001193125-26-337981.md) |
| Research and development | $m | [16.1](/filings/0000950170-24-122439.md) | [16.7 d](/filings/0001193125-26-067833.md) | [16.6](/filings/0000950170-25-064667.md) | [17.4](/filings/0000950170-25-105191.md) | [16.5](/filings/0001193125-25-264750.md) | [17.0 d](/filings/0001193125-26-067833.md) | [17.6](/filings/0001193125-26-211947.md) | [17.5](/filings/0001193125-26-337981.md) | [16.7](/filings/0001193125-25-264750.md) | [17.3 d](/filings/0001193125-26-067833.md) | [17.2](/filings/0001193125-26-211947.md) | [15.4](/filings/0001193125-26-337981.md) |
| Selling, general and administrative | $m | [74.0](/filings/0000950170-24-122439.md) | [73.8 d](/filings/0001193125-26-067833.md) | [80.2](/filings/0000950170-25-064667.md) | [70.4](/filings/0000950170-25-105191.md) | [74.1](/filings/0001193125-25-264750.md) | [85.3 d](/filings/0001193125-26-067833.md) | [87.0](/filings/0001193125-26-211947.md) | [85.3](/filings/0001193125-26-337981.md) | [82.0](/filings/0001193125-25-264750.md) | [100 d](/filings/0001193125-26-067833.md) | [85.0](/filings/0001193125-26-211947.md) | [81.2](/filings/0001193125-26-337981.md) |
| Operating income | $m | [(0.8)](/filings/0000950170-24-122439.md) | [12.1 d](/filings/0001193125-26-067833.md) | [(10.2)](/filings/0000950170-25-064667.md) | [(24.7)](/filings/0000950170-25-105191.md) | [(20.9)](/filings/0001193125-25-264750.md) | [5.9 d](/filings/0001193125-26-067833.md) | [(2.3)](/filings/0001193125-26-211947.md) | [(16.9)](/filings/0001193125-26-337981.md) | [(5.6)](/filings/0001193125-25-264750.md) | [26.9 d](/filings/0001193125-26-067833.md) | [13.8](/filings/0001193125-26-211947.md) | [7.6](/filings/0001193125-26-337981.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0000950170-24-122439.md) | [0.6 d](/filings/0001193125-26-067833.md) | [(1.8)](/filings/0000950170-25-064667.md) | [(4.0)](/filings/0000950170-25-105191.md) | [27.0](/filings/0001193125-25-264750.md) | [0.5 d](/filings/0001193125-26-067833.md) | [2.1](/filings/0001193125-26-211947.md) | [(0.4)](/filings/0001193125-26-337981.md) | [2.1](/filings/0001193125-25-264750.md) | [(1.0) d](/filings/0001193125-26-067833.md) | [(0.2)](/filings/0001193125-26-211947.md) | [(0.0)](/filings/0001193125-26-337981.md) |
| Net income | $m | [(3.1)](/filings/0000950170-24-122439.md) | [7.0 d](/filings/0001193125-26-067833.md) | [(11.6)](/filings/0000950170-25-064667.md) | [(24.2)](/filings/0000950170-25-105191.md) | [(51.7)](/filings/0001193125-25-264750.md) | [2.3 d](/filings/0001193125-26-067833.md) | [(10.5)](/filings/0001193125-26-211947.md) | [(20.9)](/filings/0001193125-26-337981.md) | [(10.6)](/filings/0001193125-25-264750.md) | [25.8 d](/filings/0001193125-26-067833.md) | [12.8](/filings/0001193125-26-211947.md) | [8.8](/filings/0001193125-26-337981.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0000950170-24-122439.md) | not reported | [(0.12)](/filings/0000950170-25-064667.md) | [(0.28)](/filings/0000950170-25-105191.md) | [(0.56)](/filings/0001193125-25-264750.md) | not reported | [(0.10)](/filings/0001193125-26-211947.md) | [(0.16)](/filings/0001193125-26-337981.md) | [(0.09)](/filings/0001193125-25-264750.md) | not reported | [0.11](/filings/0001193125-26-211947.md) | [0.06](/filings/0001193125-26-337981.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0000950170-24-122439.md) | not reported | [(0.12)](/filings/0000950170-25-064667.md) | [(0.28)](/filings/0000950170-25-105191.md) | [(0.56)](/filings/0001193125-25-264750.md) | not reported | [(0.10)](/filings/0001193125-26-211947.md) | [(0.16)](/filings/0001193125-26-337981.md) | [(0.09)](/filings/0001193125-25-264750.md) | not reported | [0.11](/filings/0001193125-26-211947.md) | [0.06](/filings/0001193125-26-337981.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [145](/filings/0000950170-23-060252.md) | [176](/filings/0000950170-25-027856.md) | [128](/filings/0000950170-24-054670.md) | [92.2](/filings/0000950170-24-089379.md) | [58.9](/filings/0000950170-24-122439.md) | [107](/filings/0001193125-26-067833.md) | [99.8](/filings/0000950170-25-064667.md) | [105](/filings/0000950170-25-105191.md) | [64.4](/filings/0001193125-25-264750.md) | [97.2](/filings/0001193125-26-337981.md) | [118](/filings/0001193125-26-211947.md) | [192](/filings/0001193125-26-337981.md) |
| Current assets | $m | [679](/filings/0000950170-23-060252.md) | [712](/filings/0000950170-25-027856.md) | [621](/filings/0000950170-24-054670.md) | [580](/filings/0000950170-24-089379.md) | [572](/filings/0000950170-24-122439.md) | [623](/filings/0001193125-26-067833.md) | [633](/filings/0000950170-25-064667.md) | [617](/filings/0000950170-25-105191.md) | [608](/filings/0001193125-25-264750.md) | [665](/filings/0001193125-26-337981.md) | [599](/filings/0001193125-26-211947.md) | [647](/filings/0001193125-26-337981.md) |
| Total assets | $m | [1,338](/filings/0000950170-23-060252.md) | [1,357](/filings/0000950170-25-027856.md) | [1,257](/filings/0000950170-24-054670.md) | [1,234](/filings/0000950170-24-089379.md) | [1,203](/filings/0000950170-24-122439.md) | [1,236](/filings/0001193125-26-067833.md) | [1,239](/filings/0000950170-25-064667.md) | [1,222](/filings/0000950170-25-105191.md) | [1,198](/filings/0001193125-25-264750.md) | [1,254](/filings/0001193125-26-337981.md) | [1,177](/filings/0001193125-26-211947.md) | [1,216](/filings/0001193125-26-337981.md) |
| Current liabilities | $m | [395](/filings/0000950170-23-060252.md) | [418](/filings/0000950170-25-027856.md) | [342](/filings/0000950170-24-054670.md) | [323](/filings/0000950170-24-089379.md) | [361](/filings/0000950170-24-122439.md) | [396](/filings/0001193125-26-067833.md) | [417](/filings/0000950170-25-064667.md) | [426](/filings/0000950170-25-105191.md) | [410](/filings/0001193125-25-264750.md) | [431](/filings/0001193125-26-337981.md) | [344](/filings/0001193125-26-211947.md) | [369](/filings/0001193125-26-337981.md) |
| Total liabilities | $m | [663](/filings/0000950170-23-060252.md) | [663](/filings/0000950170-25-027856.md) | [568](/filings/0000950170-24-054670.md) | [560](/filings/0000950170-24-089379.md) | [590](/filings/0000950170-24-122439.md) | [616](/filings/0001193125-26-067833.md) | [616](/filings/0000950170-25-064667.md) | [607](/filings/0000950170-25-105191.md) | [588](/filings/0001193125-25-264750.md) | [608](/filings/0001193125-26-337981.md) | [517](/filings/0001193125-26-211947.md) | [536](/filings/0001193125-26-337981.md) |
| Long-term debt | $m | [211](/filings/0000950170-23-060252.md) | [186](/filings/0000950170-25-027856.md) | [171](/filings/0000950170-24-054670.md) | [168](/filings/0000950170-24-089379.md) | [165](/filings/0000950170-24-122439.md) | [161](/filings/0001193125-26-067833.md) | [136](/filings/0000950170-25-064667.md) | [118](/filings/0000950170-25-105191.md) | [117](/filings/0001193125-25-264750.md) | [115](/filings/0001193125-26-337981.md) | [114](/filings/0001193125-26-211947.md) | [112](/filings/0001193125-26-337981.md) |
| Current portion of debt | $m | [12.1](/filings/0000950170-23-060252.md) | [12.2](/filings/0000950170-25-027856.md) | [12.2](/filings/0000950170-24-054670.md) | [12.2](/filings/0000950170-24-089379.md) | [12.2](/filings/0000950170-24-122439.md) | [12.2](/filings/0001193125-26-067833.md) | [12.3](/filings/0000950170-25-064667.md) | [6.1](/filings/0000950170-25-105191.md) | [6.1](/filings/0001193125-25-264750.md) | [6.1](/filings/0001193125-26-337981.md) | [6.1](/filings/0001193125-26-211947.md) | [6.1](/filings/0001193125-26-337981.md) |
| Shareholders' equity | $m | [650](/filings/0000950170-23-060252.md) | [668](/filings/0000950170-25-027856.md) | [664](/filings/0000950170-24-054670.md) | [643](/filings/0000950170-24-089379.md) | [598](/filings/0000950170-24-122439.md) | [604](/filings/0001193125-26-337981.md) | [609](/filings/0001193125-26-337981.md) | [604](/filings/0001193125-26-337981.md) | [600](/filings/0001193125-25-264750.md) | [634](/filings/0001193125-26-337981.md) | [648](/filings/0001193125-26-337981.md) | [665](/filings/0001193125-26-337981.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.9) d](/filings/0000950170-24-122439.md) | [57.1 d](/filings/0001193125-26-067833.md) | [(26.3)](/filings/0000950170-25-064667.md) | [(18.5) d](/filings/0000950170-25-105191.md) | [25.1 d](/filings/0001193125-25-264750.md) | [55.6 d](/filings/0001193125-26-067833.md) | [18.8](/filings/0001193125-26-211947.md) | [30.2 d](/filings/0001193125-26-337981.md) | [(37.0) d](/filings/0001193125-25-264750.md) | [38.2 d](/filings/0001193125-26-067833.md) | [29.7](/filings/0001193125-26-211947.md) | [74.8 d](/filings/0001193125-26-337981.md) |
| Capital expenditure | $m | [3.3 d](/filings/0000950170-24-122439.md) | [2.0 d](/filings/0001193125-26-067833.md) | [2.5](/filings/0000950170-25-064667.md) | [2.5 d](/filings/0000950170-25-105191.md) | [3.3 d](/filings/0001193125-25-264750.md) | [1.5 d](/filings/0001193125-26-067833.md) | [3.1](/filings/0001193125-26-211947.md) | [2.7 d](/filings/0001193125-26-337981.md) | [4.3 d](/filings/0001193125-25-264750.md) | [5.3 d](/filings/0001193125-26-067833.md) | [3.7](/filings/0001193125-26-211947.md) | [2.8 d](/filings/0001193125-26-337981.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [5.0](/filings/0001193125-26-211947.md) | [0.0 d](/filings/0001193125-26-337981.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [95.9](/filings/0000950170-23-060252.md) | [102](/filings/0000950170-24-054670.md) | [107](/filings/0000950170-24-089379.md) | [103](/filings/0000950170-24-122439.md) | [104](/filings/0000950170-25-064667.md) | [104](/filings/0000950170-25-105191.md) | [104](/filings/0001193125-25-264750.md) | [105](/filings/0001193125-26-211947.md) | [106](/filings/0001193125-26-337981.md) | [106](/filings/0001193125-25-264750.md) | [108](/filings/0001193125-26-211947.md) | [109](/filings/0001193125-26-337981.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 108,176,959 at 2026-07-28, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337981.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.